Is Sirolimus a Nephrotoxic Drug? A Report of Five Cases

Transplantation Proceedings

Volumn 39, Issue 5, 2007, Pages 1406-1409

  Sabry, A A ^a   Elagroudy, A E ^a   El dahshan, K F ^a   El Rahim, M A A ^a   Sobh, M A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANAMNESIS; ARTERY DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS;

EID: 34250207978     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.03.020     Document Type: Article

References (28)

1. Mayer D. Analysis and commentary. Transplantation 67 (1999) 937
2. Saunders R.N., Matcalfe M.S., and Nicoloson M.L. Rapamycin in transplantation: a review of the evidence. Kidney Int 59 (2001) 3
3. Cecka J.M. The UNOS Scientific Renal Transplant Registry-2000. Clin Transpl (2001) 1
4. Groth C.G., Backman L., Morales J.M., et al., Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 67 (1999) 1036
5. Qi S., Xu D., Peng J., et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 69 (2000) 1275
6. Manez R., Jain A., Marino I.R., et al. Comparative evaluation of tacrolimus and cyclosporin as immunosuppressive agents. Transplant Rev 9 (1995) 63
7. Shegal S.N. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 17 (1995) 660
8. Morris R.E. New small molecule immunosuppressant for transplantation: review of essential concepts. J Heart Lung Transplant 12 suppl (1993) S275
9. Terada N., Lucas J.J., Szepesi A., et al. Rapamycin blocks cell progression of activated T cells prior to events characteristics of the middle to late G1 phase of the cell cycle. J Cell Physiol 268 (1993) 22825
10. Andoh T.F., Burdmann E.A., and Bennett W.N. Nephrotxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 176 (1997) 34
11. Kahan B., Julian B.A., Pesscovitz M.D., et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporin doses in Caucasian recipient of mismatched primary renal allografts: a phase II trial. Transplantation 68 (1999) 1526
12. Groth C.G., Backman L., Morales J., et al. Sirolimus (rapamycin) based therapy in human renal transplantation. Transplantation 67 (1999) 1036
13. Kreis H., Cisterne J.M., Land W., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69 (2000) 1252
14. McAlister V.C., Gao Z., Peltekian K., et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 533 (2000) 367
15. Whiting P.H., Woo J., Adam B.H., et al. Toxicity: a comparative and combination study with cyclosoprin at immunotherapeutic dosage in the rat. Transplantation 52 (1999) 203
16. DiJoseph J.F., Sharma R.N., and Chang J.Y. The effect of rapamycin on kidney function in the Sprague-Daweley rat. Transplantation 53 (1992) 507
17. Sabbatini M., Sansone G., Uccello F., et al. Acute effects of rapamycin on glomerular dynamics; a micropuncture study in the rat. Transplantation 69 (2000) 1946
18. Andoth T.F., Burbmann E.A., Fransechini N., et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 62 (1996) 311
19. Andoh T.F., Burdmann E.A., Fransechiui N., et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 50 (1996) 1110
20. Nath K.A. tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20 (1992) 1
21. Fervenza F.C., Fitzpatrick P.M., Mertz J., et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 19 (2004) 1288
22. Remuzzi G., and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339 (1998) 1448
23. Budde K.T.J., Oppenheimer F., Fritsche L., et al. Improvement of renal transplant function in patients with chronic calcinurin-inhibit (CNI) nephrotoxicity and low proteinuria one year after conversion to sirolimus (SRL). Am J Transplant 3 (2003) 198A
24. Hadaya K., Wissing M., Emine B., et al. Conversion to sirolimus after renal transplantation: high failure rate due to nephrotic proteinuria and other adverse events. ASN Annual Meeting-San Diego. J Am Soc Nephrol 14 (2003) 185A
25. Jim B., Doyle A., and Bloom R.D. Rapamycin is associated with worsening proteinuria in transplant patients with renal injury: a report of four cases. ASN Annual Meeting-San Diego. J Am Soc Nephrol 14 (2003) 65A
26. Barone G.W., Gurley B.J., Abul-Ezz S.R., et al. Sirolimusinduced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 42 (2003) 202
27. Robson M., Cote I., Abbs I., et al. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?. Am J Transplant 3 (2003) 324
28. Saikali J.A., Truong L.D., and Suki W.N. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 3 (2003) 229